Publication for CD200 and BTLA

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CD200	CD200 molecule	4345			[link]
hsa	BTLA	B and T lymphocyte associated	151888

Pubmed ID	Priority	Text
31572674	0.98	CD200 and BTLA and gene deletions in RB1, TP53, CTCF as has been reported earlier.
	0.97	CD200 and heterozygous deletion of BTLA, we identified a case of ALL relapse with heterozygous deletion of CD200 and a homozygous deletion of BTLA.
	0.96	CD200, BTLA, CASP8AP2, and MYB).
	0.96	BTLA, CD200, VPREB1 which are associated with inferior event-free and overall survival; DMD with relapse, TBL1XR1 and TP53 with chemo-resistance; EZH2, PAR1 region, and P2RY8-CRLF2 with poor prognosis; CASP8AP2, NF1, and SUZ12 associated with poor response to induction therapy are included in this dMLPA panel and useful for further risk stratification in cytogenetically good risk B-ALL cases.
	0.95	CD200, and BTLA (Figure 4; Supplementary Figure S2).
	0.95	CD200, BTLA, CASP8AP2, MYB) influencing the risk stratification of these good risk category.
27933341	0.98	BTLA and CD200 genes in ETV6/RUNX1-positive children with ALL.
	0.97	CD200 and BTLA.
	0.97	BTLA and CD200 are very early and essential events in leukemia development.
	0.94	CD200/BTLA deletions was associated with poor treatment outcome in patients treated according to the EORTC-CLG 58951 protocol, with inferior event-free survival and overall survival (Ghazavi et al.).
	0.93	BTLA/CD200 deletions have recently been reported in adult B cell precursor acute lymphoblastic leukemia (ALL) pts.
19129520	0.98	BTLA/CD200 and the Cumulative Incidence of Any Relapse in the Original Cohort
	0.98	BTLA/CD200 alteration status.
	0.93	BTLA and CD200).
	0.85	BTLA/CD200 were associated with a poor outcome only in the original cohort.
24246699	0.97	BTLA, CD200, TOX), the glucocorticoid receptor NR3C1, transcriptional regulators and co-activators including TBL1XR1, ETV6 and ERG, and regulators of chromatin structure and epigenetic regulators (CTCF, CREBBP).
30101129	0.97	CD200 which are the ligands for PD-1, CD161, BTLA, and SIRP-alpha, and secretion of inhibitory enzymes, Indoleamine 2, 3-dioxygenase (IDO) and IL4I1 leads to impaired T cell mediated cytotoxicity and T cell exhaustion.
27577071	0.96	CD200, PD-1, CD137L, CD273, CD274, CTLA-4, TIM-3, CD137, CD158, CD160, B-and T-lymphocyte attenuator (BTLA), CD28, CD27, TIGIT and CD278, in circulating CD4+ and CD8+ T cells that were derived from normal donors (n = 10) or esophageal cancer patients (n = 10, Figure 1).
	0.96	CD200, PD-1, BTLA, CD137L, CD273 and CD274) in CD4+ and CD8+ T cells of normal donors' peripheral blood mononuclear cells (PBMC) and esophageal cancer patients' PBMC.
	0.90	CD200, BTLA, CD28, CD27 and TIGIT in cancer patients' CD4+ T cells were significantly lower than that of normal donors (cancer patients vs. healthy donors, 7.386 +- 0.7313% vs. 12.68 +- 1.134%, p = 0.0010; 93.48 +- 0.8471% vs. 96.95 +- 0.3344%, p = 0.0013; 88.98 +- 2.499% vs. 97.76 +- 0.6576%, p = 0.0032; 74.39 +- 4.781% vs. 94.99 +- 0.7738%, p = 0.0005; 80.95 +- 3.544% vs. 97.36 +- 0.4241%, p = 0.0002; Figure 2).
28428203	0.96	BTLA, SAP, CD200, CXCL13, IL-21, C-MAF, BCL6, and BLIMP1) by TSLP-DC-induced CXCR5hiPD1hi cells was similar to tonsillar Tfh and GC Tfh cells.
	0.93	BTLA, CXCR5, CXCL13, ICOS, PD1, SAP, CD200, and C-MAF) as compared with CXCR5loPD1lo cells (Fig. 4 and Fig. S2).
	0.59	BTLA, CD200, SAP, or C-MAF protein.
32010613	0.95	CD200/BTLA deletions do not affect prognosis within this genetic subtype.
	0.56	CD200/BTLA deletions act as predictive biomarkers in pediatric BCP-ALL without any known genetic lesions, and are associated with <8-year EFS.
30190342	0.94	BTLA, CD200 and RB1 were deleted in 30, 27, 21, 17 and 16 cases, respectively (25.9%, 23%, 18.1%, 17.2%, 14.6%, and 13.8%) (Figure 1C).
31096713	0.93	CD200 and herpes virus entry mediator (HVEM), can suppress T cell activation through CD200-CD200R and HVEM-BTLA interactions.
30634925	0.92	CD200, CD40LG, ADORA2A, TNFSF14, BTLA, CD160, CD44, CD48, CD28, VTCN1, CD200R1, NRP1, TMIGD2, ICOS, and TNFSF15) had significantly higher expression levels in the lower-TMB subtype than in the higher-TMB subtype of at least 6 cancer types.
28303531	0.90	BTLA, CD200, TOX, NR3C1, TBL1XR1, ETV6, ERG genes reported to be linked with acute lymphoblastic leukaemia
19039135	0.89	CD200/BTLA, FHIT, KRAS, IL3RA/CSF2RA, NF1, PTCH, TBL1XR1, TOX, WT1, NR3C1 and DMD (table S8 and fig. S11); and progression of intrachromosomal amplification of chromosome 21, a poor prognostic marker in childhood ALL (fig. S12).
24530057	0.67	BTLA, CTLA-4, CD200 and even PD-1 at later time points, as well as the lack of the CD8+ T cell biased molecules including 2B4 and Pilra, suggests qualitative differences in the negative regulatory circuits for CD4+ and CD8+ T cells during the same chronic infection.
29664013	0.64	BTLA, IDO1, IDO2, ICOS, CD27, and CD72 had their highest expression in the tumors with the strongest T cell infiltration (Figure 2C), while CD200 had no clear association with CICs.